Hsiao-Ching Huang1, Mary H Smart1, Ashwini Zolekar1, Huiwen Deng1, Colin C Hubbard2, Kent F Hoskins3, Naomi Y Ko4, Jenny S Guadamuz5,6, Gregory S Calip7,8. 1. Department of Pharmacy Systems, Outcomes and Policy, University of Illinois Chicago, Chicago, IL, USA. 2. Division of Hospital Medicine, Department of Medicine, University of California San Francisco, San Francisco, CA, USA. 3. Division of Hematology and Oncology, University of Illinois Chicago, Chicago, IL, USA. 4. Section of Hematology Oncology, Boston Medical Center, Boston University School of Medicine, Boston, MA, USA. 5. Program on Medicines and Public Health, Titus Family Department of Clinical Pharmacy, University of Southern California School of Pharmacy, Los Angeles, CA, USA. 6. Leonard D. Schaeffer Center for Health Policy and Economics, University of Southern California, Los Angeles, CA, USA. 7. Department of Pharmacy Systems, Outcomes and Policy, University of Illinois Chicago, Chicago, IL, USA. gcalip@uic.edu. 8. Center for Pharmacoepidemiology and Pharmacoeconomic Research, University of Illinois Chicago, 833 South Wood Street, MC 871, Chicago, IL, 60612, USA. gcalip@uic.edu.
Abstract
PURPOSE: There are approximately 150,000 women living with metastatic breast cancer (mBC) in the United States. Disparities in de novo mBC incidence and mortality exist across race/ethnicity, socioeconomic status (SES), and rurality. However, how SES and rurality independently impact mBC outcomes across different racial/ethnic groups is not fully understood. The purpose of this study was to determine the impact of SES and rurality on cancer-specific mortality among women with mBC by race/ethnicity. METHODS: We conducted a large, population-based retrospective cohort study in women aged 18 + years diagnosed with de novo mBC using the Surveillance, Epidemiology and End Results Census Tract-level SES and Rurality Database (2000-2015). Associations between SES/rurality and cancer-specific mortality were determined using Fine and Gray regression models. Subdistribution hazard ratios (SHR) and 95% confidence intervals (CI) by race/ethnicity and hormone receptor (HR) status were calculated. RESULTS: A cohort of 33,976 women were included with the majority being White (67%), 17% Black, 0.4% American Indian/Alaskan Native, 6% Asian/Pacific Islander, and 10% Latina/Hispanic. We observed the greatest increased risk of BC mortality among Black women with HR-negative mBC residing in neighborhoods with lower SES (lowest versus highest quintile: SHR 1.38, 95% CI 1.00-1.90) and in rural areas compared to urban areas (SHR 1.27, 95% CI 1.01-1.59). CONCLUSION: Overall, BC-specific survival among women with de novo mBC differs by race/ethnicity, with the greatest adverse impacts of SES and rurality affecting Black women with HR-negative disease.
PURPOSE: There are approximately 150,000 women living with metastatic breast cancer (mBC) in the United States. Disparities in de novo mBC incidence and mortality exist across race/ethnicity, socioeconomic status (SES), and rurality. However, how SES and rurality independently impact mBC outcomes across different racial/ethnic groups is not fully understood. The purpose of this study was to determine the impact of SES and rurality on cancer-specific mortality among women with mBC by race/ethnicity. METHODS: We conducted a large, population-based retrospective cohort study in women aged 18 + years diagnosed with de novo mBC using the Surveillance, Epidemiology and End Results Census Tract-level SES and Rurality Database (2000-2015). Associations between SES/rurality and cancer-specific mortality were determined using Fine and Gray regression models. Subdistribution hazard ratios (SHR) and 95% confidence intervals (CI) by race/ethnicity and hormone receptor (HR) status were calculated. RESULTS: A cohort of 33,976 women were included with the majority being White (67%), 17% Black, 0.4% American Indian/Alaskan Native, 6% Asian/Pacific Islander, and 10% Latina/Hispanic. We observed the greatest increased risk of BC mortality among Black women with HR-negative mBC residing in neighborhoods with lower SES (lowest versus highest quintile: SHR 1.38, 95% CI 1.00-1.90) and in rural areas compared to urban areas (SHR 1.27, 95% CI 1.01-1.59). CONCLUSION: Overall, BC-specific survival among women with de novo mBC differs by race/ethnicity, with the greatest adverse impacts of SES and rurality affecting Black women with HR-negative disease.
Authors: Li Tao; Laura Chu; Lisa I Wang; Lisa Moy; Melissa Brammer; Chunyan Song; Marjorie Green; Allison W Kurian; Scarlett L Gomez; Christina A Clarke Journal: Cancer Causes Control Date: 2016-08-05 Impact factor: 2.506
Authors: Ramy R Saleh; Michelle B Nadler; Alexandra Desnoyers; Danielle L Rodin; Husam Abdel-Qadir; Eitan Amir Journal: Sci Rep Date: 2020-03-05 Impact factor: 4.379
Authors: Smita Bhatia; Wendy Landier; Electra D Paskett; Katherine B Peters; Janette K Merrill; Jonathan Phillips; Raymond U Osarogiagbon Journal: J Natl Cancer Inst Date: 2022-07-11 Impact factor: 11.816